Tofacitinib Citrate Patent Expiration
Tofacitinib Citrate is Used for treating moderate to severe ulcerative colitis and rheumatoid arthritis. It was first introduced by Pf Prism Cv
Tofacitinib Citrate Patents
Given below is the list of patents protecting Tofacitinib Citrate, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Xeljanz Xr | US10639309 | Tofacitinib oral sustained release dosage forms | Mar 14, 2034 | Pfizer |
| Xeljanz Xr | US11253523 | Tofacitinib oral sustained release dosage forms | Mar 14, 2034 | Pfizer |
| Xeljanz Xr | US9937181 | Tofacitinib oral sustained release dosage forms | Mar 14, 2034 | Pfizer |
| Xeljanz | USRE41783 | Pyrrolo[2,3-D]pyrimidine compounds | Dec 08, 2025 | Pfizer |
| Xeljanz | USRE41783 | Pyrrolo[2,3-D]pyrimidine compounds | Dec 08, 2025 | Pf Prism Cv |
| Xeljanz Xr | USRE41783 | Pyrrolo[2,3-D]pyrimidine compounds | Dec 08, 2025 | Pfizer |
| Xeljanz | US6965027 | Crystalline 3-{4-methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile citrate |
Mar 25, 2023
(Expired) | Pf Prism Cv |
| Xeljanz | US6965027 | Crystalline 3-{4-methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile citrate |
Mar 25, 2023
(Expired) | Pf Prism Cv |
| Xeljanz Xr | US6956027 | N-terminally chemically modified protein compositions and methods |
Mar 25, 2023
(Expired) | Pfizer |
| Xeljanz Xr | US6965027 | Crystalline 3-{4-methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile citrate |
Mar 25, 2023
(Expired) | Pfizer |
| Xeljanz | US7301023 | Chiral salt resolution |
May 23, 2022
(Expired) | Pf Prism Cv |
| Xeljanz | US6956041 | Pyrrolo[2,3-d]pyrimidine compounds |
Dec 08, 2020
(Expired) | Pf Prism Cv |
| Xeljanz | US7091208 | Pyrrolo[2,3-D]pyrimidine compounds |
Dec 08, 2020
(Expired) | Pf Prism Cv |
| Xeljanz | US7265221 | Pyrrolo[2,3-d]pyrimidine compounds |
Dec 08, 2020
(Expired) | Pf Prism Cv |
| Xeljanz | US7265221 | Pyrrolo[2,3-d]pyrimidine compounds |
Dec 08, 2020
(Expired) | Pf Prism Cv |
| Xeljanz | US7301023 | Chiral salt resolution |
Dec 08, 2020
(Expired) | Pf Prism Cv |
| Xeljanz | US7842699 | Pyrrolo[2,3-D]pyrimidine compounds |
Dec 08, 2020
(Expired) | Pf Prism Cv |
| Xeljanz Xr | US6956041 | Pyrrolo[2,3-d]pyrimidine compounds |
Dec 08, 2020
(Expired) | Pfizer |
| Xeljanz Xr | US7091208 | Pyrrolo[2,3-D]pyrimidine compounds |
Dec 08, 2020
(Expired) | Pfizer |
| Xeljanz Xr | US7265221 | Pyrrolo[2,3-d]pyrimidine compounds |
Dec 08, 2020
(Expired) | Pfizer |
| Xeljanz Xr | US7301023 | Chiral salt resolution |
Dec 08, 2020
(Expired) | Pfizer |
| Xeljanz Xr | US7842699 | Pyrrolo[2,3-D]pyrimidine compounds |
Dec 08, 2020
(Expired) | Pfizer |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Tofacitinib Citrate's patents.
Latest Legal Activities on Tofacitinib Citrate's Patents
Given below is the list recent legal activities going on the following patents of Tofacitinib Citrate.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Year, Large Entity | 12 Oct, 2023 | US10639309 |
| Expire Patent Critical | 02 Jan, 2023 | US7842699 |
| Maintenance Fee Reminder Mailed Critical | 18 Jul, 2022 | US7842699 |
| Recordation of Patent Grant Mailed Critical | 22 Feb, 2022 | US11253523 |
| Patent Issue Date Used in PTA Calculation Critical | 22 Feb, 2022 | US11253523 |
| Email Notification Critical | 03 Feb, 2022 | US11253523 |
| Issue Notification Mailed Critical | 02 Feb, 2022 | US11253523 |
| Mailing Corrected Notice of Allowability | 27 Jan, 2022 | US11253523 |
| Email Notification Critical | 27 Jan, 2022 | US11253523 |
| Dispatch to FDC | 25 Jan, 2022 | US11253523 |
Tofacitinib Citrate's Family Patents
Explore Our Curated Drug Screens
Tofacitinib Citrate Generic API Manufacturers
Several generic applications have been filed for Tofacitinib Citrate. The first generic version for Tofacitinib Citrate was by Ajanta Pharma Ltd and was approved on Jun 1, 2021. And the latest generic version is by Aurobindo Pharma Ltd and was approved on Jun 3, 2024.
Given below is the list of companies who have filed for Tofacitinib Citrate generic, along with the locations of their manufacturing plants worldwide.
1. AJANTA PHARMA LTD
Ajanta Pharma Ltd has filed for 1 generic for Tofacitinib Citrate. Given below are the details of the strengths of this generic introduced by Ajanta Pharma Ltd.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| EQ 10MG BASE | tablet | Discontinued | ORAL | N/A | Jun 1, 2021 |
Manufacturing Plant Locations New
Ajanta Pharma Ltd's manufacturing plants are situated in 1 country - India. Given below are the details of these plant locations as well as the firm names of Ajanta Pharma Ltd as present at those locations.
| Country | City | Firm Name | ||
|---|---|---|---|---|
| India |
| |||
2. AUROBINDO PHARMA LTD
Aurobindo Pharma Ltd has filed for 1 generic for Tofacitinib Citrate. This eq 11mg base version comes by the name TOFACITINIB. Given below are the details of the strengths of this generic introduced by Aurobindo Pharma Ltd.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| EQ 11MG BASE | tablet, extended release | Discontinued | ORAL | N/A | Jun 3, 2024 |
Manufacturing Plant Locations New
Aurobindo Pharma Ltd's manufacturing plants are situated in 1 country - India. Given below are the details of these plant locations as well as the firm names of Aurobindo Pharma Ltd as present at those locations.
| Country | City | Firm Name | ||
|---|---|---|---|---|
| India |
| |||
3. HIKMA
Hikma Pharmaceuticals Usa Inc has filed for 1 generic for Tofacitinib Citrate. Given below are the details of the strengths of this generic introduced by Hikma.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| EQ 1MG BASE/ML | solution | Discontinued | ORAL | N/A | Sep 25, 2023 |
Manufacturing Plant Locations New
Hikma's manufacturing plants are situated in 3 countries - United States, Portugal, Jordan. Given below are the details of these plant locations as well as the firm names of Hikma as present at those locations.
| Country | City | Firm Name | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| United States |
| |||||||||
| Portugal |
| |||||||||
| Jordan |
| |||||||||
4. MICRO LABS
Micro Labs Ltd has filed for 1 generic for Tofacitinib Citrate. Given below are the details of the strengths of this generic introduced by Micro Labs.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| EQ 5MG BASE | tablet | Discontinued | ORAL | N/A | Mar 13, 2023 |
Manufacturing Plant Locations New
Micro Labs's manufacturing plants are situated in 1 country - India. Given below are the details of these plant locations as well as the firm names of Micro Labs as present at those locations.
| Country | City | Firm Name | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| India |
| |||||||||
5. ZYDUS PHARMS
Zydus Pharmaceuticals Usa Inc has filed for 3 different strengths of generic version for Tofacitinib Citrate. Out of these eq 11mg base version comes by the name TOFACITINIB, eq 22mg base version comes by the name TOFACITINIB. Given below are the details of the strengths of this generic introduced by Zydus Pharms.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| EQ 11MG BASE | tablet, extended release | Discontinued | ORAL | N/A | Aug 19, 2021 |
| EQ 22MG BASE | tablet, extended release | Discontinued | ORAL | N/A | Aug 19, 2021 |
| EQ 5MG BASE | tablet | Discontinued | ORAL | N/A | Mar 13, 2023 |